Abstract
Patients with acute myelogenous leukemia or myelodysplastic syndrome may respond to farnesyl transferase inhibitors (FTIs) with partial or complete response rates noted in about 30% of such patients. FTIs prevent the attachment of a lipid farnesyl moiety to dependent proteins prior to their insertion into the plasma membrane and thereby prevent activity of these prenylation-dependent proteins, but their mechanism of tumor suppression remains unknown. Many patients receiving FTIs do experience myelosuppression. In this work, the in vitro effects of the FTI, R115777 on normal and leukemic hematopoiesis have been examined as have its effects on apoptosis induction and cell cycle profile in both leukemic blasts and normal CD34+ cells. R115777 was inhibitory to normal CD34+ cell proliferation and to leukemic blast cells, but did not affect long-term culture initiating cell frequency nor NOD-SCID reconstituting capacity. No induction of apoptosis or cell cycle changes were noted in AML blasts. These data suggest that myelosuppression with R115777 occurs largely at the intermediate to late progenitor stage of hematopoiesis and that cyclic use might avoid long-term marrow suppression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Khosvari-Far R, Cox AD, Kato K, Der CJ . Protein prenylation: key to ras function and cancer intervention. Cell Growth Diff 1992; 3: 461–469.
End DW . Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest New Drugs 1999; 17: 241–258.
Bearupe DM, Kurzrock RA . RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol 1999; 17: 1071–1079.
Cox AD, Der CJ . Farnesyl inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta 1997; 1333: F51–F71.
Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM et al. The phosphoinositide 3-OH-kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 2000; 20: 139–148.
End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angiboud P et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001; 61: 131–137.
Rowinsky EK, Windle JJ, Van Hoff DD . Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999; 17: 3631–3652.
Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase I clinical–laboratory correlative trial. Blood 2001; 97: 3361–3369.
Sutherland HJ, Eaves CJ, Lansdorp PM, Thacker JD, Hogge D . Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood 1991; 78: 666–672.
Blair A, Sutherland HJ . Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol 2000; 28: 660–671.
Liesveld JL, Frediani KE, Harbol AW, DiPersio JF, Abboud CN . Characterization of the adherence of normal and leukemic CD34+ cells to endothelial monolayers. Leukemia 1994; 12: 211–217.
Liesveld JL, Rosell K, Panoskaltsis N, Belanger T, Harbol A, Abboud CN . Response of human CD34+ cells to CXC, CC, and CX3C chemokines: implications for cell migration and activation. J Hematother Stem Cell Res 2001; 10: 643–655.
Reykdal S, Abboud C, Liesveld JL . Effect of nitric oxide production and oxygen tension on progenitor preservation in ex vivo culture. Exp Hematol 1999; 27: 441–450.
Ohkanda J, Knowles DB, Blaskovich MA, Sebti SM, Hamilton AD . Inhibitors of protein farnesyltransferase as novel anticancer agents. Curr Top Med Chem 2002; 2: 303–323.
Ailles LE, Gerhard B, Kawagoe H, Hogge DE . Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 1999; 94: 1761–1772.
Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000; 18: 927–941.
Punt CJ, van Maanen L, Bol CJ, Seifert WF, Wagener DJ . Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs 2001; 12: 193–197.
Lebowitz PF, Sakamuro D, Prendergast GC . Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res 1997; 57: 708–713.
Epp-Lorenzion L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A et al. A peptidomimetic inhibitor of farnesyl protein transferase blocks the anchorage-dependent and independent growth of human tumor cell lines. Cancer Res 1995; 55: 5302–5309.
Gouill SL, Pellat-Deceunynck C, Harousseau J-L, Rapp J-J, Robillard N, Bataille R et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 2002; 16: 164–167.
Du W, Liu A, Prendergast GC . Activation of the IGF-PI3’K pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res 1999; 59: 4208–4212.
Prendergast G . Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol 2000; 12: 166–173.
Moasser MM, Sepp-Lorenzion L, Kohl NE, Oliff A, Balog A, Su DS et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 1998; 95: 1369–1374.
Acknowledgements
We thank Louise Haskins for aid in manuscript preparation and Dr David End (Johnson and Johnson Pharmaceutical Research and Development) for provision of R115777 and helpful comments. Supported by a Translational Research Grant from the Leukemia & Lymphoma Society of America. JLL is a Clinical Scholar of the Leukemia and Lymphoma Society of America.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Liesveld, J., Lancet, J., Rosell, K. et al. Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis. Leukemia 17, 1806–1812 (2003). https://doi.org/10.1038/sj.leu.2403063
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403063